Systemic AAV vectors for widespread and targeted gene delivery in rodents.
Rosemary C ChallisSripriya Ravindra KumarKen Y ChanCollin ChallisKeith BeadleMin J JangHyun Min KimPradeep S RajendranJohn D TompkinsKalyanam ShivkumarBenjamin E DevermanViviana GradinaruPublished in: Nature protocols (2019)
We recently developed adeno-associated virus (AAV) capsids to facilitate efficient and noninvasive gene transfer to the central and peripheral nervous systems. However, a detailed protocol for generating and systemically delivering novel AAV variants was not previously available. In this protocol, we describe how to produce and intravenously administer AAVs to adult mice to specifically label and/or genetically manipulate cells in the nervous system and organs, including the heart. The procedure comprises three separate stages: AAV production, intravenous delivery, and evaluation of transgene expression. The protocol spans 8 d, excluding the time required to assess gene expression, and can be readily adopted by researchers with basic molecular biology, cell culture, and animal work experience. We provide guidelines for experimental design and choice of the capsid, cargo, and viral dose appropriate for the experimental aims. The procedures outlined here are adaptable to diverse biomedical applications, from anatomical and functional mapping to gene expression, silencing, and editing.
Keyphrases
- gene therapy
- gene expression
- randomized controlled trial
- dna methylation
- copy number
- induced apoptosis
- poor prognosis
- crispr cas
- heart failure
- high resolution
- genome wide
- clinical practice
- high dose
- type diabetes
- young adults
- metabolic syndrome
- low dose
- minimally invasive
- atrial fibrillation
- decision making
- cell proliferation
- signaling pathway
- high fat diet induced
- long non coding rna
- skeletal muscle
- endoplasmic reticulum stress
- insulin resistance
- genome wide identification
- single molecule
- childhood cancer